Mainz Biomed ’s (NASDAQ: MYNZ) ColoFuture Study Reveals “Groundbreaking Results”: ColoAlert® Raises The Bar For Colorectal Cancer Detection

Throughout the world, colorectal cancer has emerged as the third most prevalent form of cancer. Traditionally observed in individuals aged 45 and above, this malignancy is now displaying a troubling trend of affecting younger individuals. Startling data indicates a consistent increase in newly…#coloalert #mainz #colofuturestudy #mainzbiomed #colofuture #crc #tarrinkhairitaraki #commercialoperations #emea #tarrin
Source: Reuters: Health - Category: Consumer Health News Source Type: news